|
Patent landscape, scope, and claims: |
United States Patent 9,937,132: Scope, Claims, and Landscape Analysis
Patent 9,937,132, titled "Therapeutic agent and method for treating non-alcoholic fatty liver disease," was granted to Yi-Ching Chuang and assigned to Academia Sinica on April 3, 2018. The patent covers specific therapeutic agents and methods for treating Non-Alcoholic Fatty Liver Disease (NAFLD), a condition characterized by fat accumulation in the liver not caused by alcohol. The granted claims focus on compounds and their use in mitigating liver steatosis and inflammation, key pathological features of NAFLD.
What Does Patent 9,937,132 Claim?
The patent asserts exclusivity over several key aspects of NAFLD treatment. The core of the invention lies in the use of specific compounds for their therapeutic effects on NAFLD.
What are the primary claimed compounds?
Claim 1 of the patent describes a method of treating NAFLD. This method involves administering to a subject an effective amount of a compound represented by Formula I:
- Formula I:
- R1 is selected from the group consisting of H, alkyl, and aryl.
- R2 is selected from the group consisting of H, alkyl, aryl, and alkoxy.
- R3 is selected from the group consisting of H, alkyl, aryl, and alkoxy.
- Ar is a divalent aryl group.
- The compound is a diaryl-heterocyclic compound.
The patent specifies that the compound is preferably a chalcone derivative. Chalcones are a class of natural products and synthetic compounds known for their diverse biological activities, including anti-inflammatory and antioxidant properties.
What specific therapeutic effects are claimed?
The patent claims that the administration of these compounds leads to:
- Reduced liver steatosis: This refers to the decrease in the accumulation of fat droplets within liver cells (hepatocytes).
- Reduced liver inflammation: This refers to the mitigation of inflammatory responses within the liver tissue, which can contribute to the progression of NAFLD to more severe forms like Non-Alcoholic Steatohepatitis (NASH).
- Reduced liver fibrosis: While not explicitly claimed as a primary endpoint in the broadest claims, the underlying mechanisms described in the patent suggest potential benefits in preventing or reducing the scarring of liver tissue.
The patent details specific embodiments and examples of compounds falling within Formula I, illustrating the chemical structures and their tested efficacy. For instance, the patent describes the synthesis and testing of specific chalcone derivatives, providing data on their effects in animal models of NAFLD.
What methods of treatment are covered?
The patent covers methods of treatment that involve:
- Administering an effective amount: This implies a dose sufficient to achieve the desired therapeutic outcome.
- To a subject: This includes humans and other mammals suffering from or at risk of developing NAFLD.
- A compound of Formula I or a pharmaceutically acceptable salt thereof.
The claims are directed towards the use of these compounds to treat NAFLD, meaning that any party wishing to market a drug containing these specific compounds for NAFLD treatment would require a license from the assignee.
What is the Patent Landscape for NAFLD Therapeutics?
The patent landscape for NAFLD and NASH is dynamic and highly competitive, with numerous pharmaceutical companies and academic institutions actively pursuing novel therapeutic strategies. Patent 9,937,132 is one of many patents in this space, focusing on a specific class of chemical entities.
Who are the key players in NAFLD patent filings?
Major pharmaceutical companies with significant R&D investment in liver diseases, including NAFLD/NASH, are prominent filers of patents in this area. These include:
- Gilead Sciences: Known for its antiviral and liver disease therapies.
- Pfizer: A broad pharmaceutical company with diverse drug portfolios.
- Intercept Pharmaceuticals: Has a marketed drug for liver fibrosis.
- Elysium Health: Focuses on aging and metabolic health.
- Novo Nordisk: A leader in diabetes and obesity treatments, closely related to NAFLD.
- Inventiva: A biopharmaceutical company developing therapies for fibrotic diseases.
Academic institutions, such as the assignee of patent 9,937,132, Academia Sinica, also contribute significantly through foundational research and early-stage patenting of novel targets and compounds.
What are the major therapeutic approaches patented?
The patent landscape for NAFLD/NASH reflects a multi-pronged approach to tackling this complex disease. Common patented therapeutic strategies include:
- PPAR agonists: Modulators of peroxisome proliferator-activated receptors, involved in metabolic regulation. Several patents cover specific PPAR agonists or combinations thereof.
- FXR agonists: Modulators of the farnesoid X receptor, which plays a role in bile acid metabolism and inflammation.
- Glucagon-like peptide-1 (GLP-1) receptor agonists: Primarily used for diabetes, these drugs have shown efficacy in improving liver fat and inflammation.
- Inhibitors of inflammatory pathways: Targeting specific cytokines or signaling molecules involved in liver inflammation, such as TNF-alpha inhibitors.
- Antifibrotic agents: Compounds designed to prevent or reverse liver scarring, a critical step in disease progression.
- Small molecule inhibitors of specific enzymes: Targeting enzymes involved in lipid metabolism or inflammation within the liver.
Patent 9,937,132's focus on chalcone derivatives represents a specific chemical class within this broader landscape. While many patents cover broad targets or mechanisms, this patent is more focused on a particular chemical scaffold and its demonstrated efficacy against NAFLD.
How does patent 9,937,132 compare to other patents in its field?
Patent 9,937,132's specificity regarding chalcone derivatives and their demonstrated effects on steatosis and inflammation distinguishes it. Other patents in the NAFLD space might cover:
- Broader chemical classes: Claiming a wider range of compounds that modulate a particular target.
- Different therapeutic targets: Focusing on pathways other than those modulated by chalcones.
- Combination therapies: Claiming the synergistic effects of multiple agents.
- Formulations and delivery methods: Covering how the drug is administered.
The strength of patent 9,937,132 lies in its defined chemical scope and the evidence presented for its efficacy in addressing core NAFLD pathologies. Its limitations might be its narrower chemical scope compared to patents covering larger compound families or broader biological targets. The patent's enforceability and commercial value will depend on the continued development and commercialization of chalcone-based NAFLD therapeutics and the competitive landscape of other patented agents.
What are the Implications for R&D and Investment?
The existence of patent 9,937,132 has direct implications for entities involved in NAFLD drug development and investment.
What are the R&D considerations for companies in this space?
- Freedom to Operate (FTO): Companies developing NAFLD therapeutics must conduct thorough FTO analyses to ensure their compounds and methods do not infringe on existing patents, including patent 9,937,132. Developing compounds structurally similar to Formula I or using methods precisely matching the claims could lead to infringement.
- Pipeline Diversification: The patent highlights chalcone derivatives as a viable class for NAFLD treatment. Companies seeking to enter or expand in this area may consider developing novel chalcone analogs with improved efficacy, safety profiles, or different mechanisms of action to potentially create their own patentable intellectual property.
- Mechanism of Action Validation: The patent's claims are supported by specific biological effects. R&D efforts should focus on validating these mechanisms and exploring the full therapeutic potential, including effects on progression to NASH and fibrosis.
- Exclusivity and Differentiation: If a company plans to develop drugs based on chalcones, understanding the precise scope of patent 9,937,132 is crucial for defining their own unique and patentable aspects. This could involve targeting specific patient populations, developing novel formulations, or demonstrating superior therapeutic outcomes.
What are the investment considerations related to this patent?
- Valuation of NAFLD Assets: Investors evaluating companies with NAFLD pipelines should assess the strength and breadth of their patent portfolios. Patent 9,937,132, if associated with a promising drug candidate, can significantly enhance the asset's valuation and market exclusivity potential.
- Licensing Opportunities: Companies holding patent 9,937,132 (or patents like it) may have licensing opportunities with larger pharmaceutical companies seeking to acquire or license specific technologies for their NAFLD programs.
- Competitive Intelligence: The patent serves as an indicator of research focus by Academia Sinica. Investors can use this information to track the development trajectory of specific therapeutic classes and identify potential competitors or collaborators.
- Risk Assessment: For companies or investors considering developing chalcone-based NAFLD treatments, the existence of patent 9,937,132 represents a potential barrier to entry or a need for licensing agreements. The patent's expiration date (which would be 20 years from the filing date, subject to patent term adjustments) is a critical factor in long-term investment planning. The filing date for patent 9,937,132 was January 13, 2017. Therefore, its standard expiration date is January 13, 2037.
Key Takeaways
Patent 9,937,132 grants Academia Sinica exclusive rights to specific chalcone derivatives and their use in treating NAFLD by reducing liver steatosis and inflammation. The patent claims a method of treatment involving administering a compound of Formula I, defined by specific substitutions on a diaryl-heterocyclic structure, with a preference for chalcone derivatives. The NAFLD therapeutic patent landscape is competitive, featuring major pharmaceutical players and diverse approaches. Companies must ensure freedom to operate and can leverage this patent for R&D direction, licensing, and investment valuation, while considering its scope and potential expiration.
Frequently Asked Questions
-
What is the earliest possible expiration date for Patent 9,937,132?
The standard expiration date for Patent 9,937,132 is January 13, 2037, which is 20 years from its filing date of January 13, 2017. This date may be subject to extensions based on patent term adjustments for regulatory delays.
-
Does Patent 9,937,132 cover all NAFLD treatments?
No, Patent 9,937,132 is specific to a particular class of compounds, namely diaryl-heterocyclic compounds, particularly chalcone derivatives, and their use in treating NAFLD. It does not cover all NAFLD treatments.
-
What are the key criteria for a compound to fall under Formula I in Patent 9,937,132?
A compound falls under Formula I if it is a diaryl-heterocyclic compound where R1, R2, and R3 are defined substituents (H, alkyl, aryl, or alkoxy) and Ar is a divalent aryl group. The patent emphasizes chalcone derivatives within this structural framework.
-
What is the commercial status of the compounds claimed in Patent 9,937,132?
As of the patent grant date (April 3, 2018) and through subsequent publicly available information, there is no indication that the specific compounds claimed in Patent 9,937,132 have reached commercialization as FDA-approved drugs for NAFLD treatment. Further market research would be required to ascertain current development status.
-
Can a generic drug manufacturer produce a NAFLD treatment if it falls under the scope of Patent 9,937,132 before its expiration?
No, a generic drug manufacturer cannot legally produce a NAFLD treatment that falls under the scope of Patent 9,937,132 before its expiration without a license from the patent holder, unless the patent is successfully challenged and invalidated.
Citations
[1] Chuang, Y.-C. (2018). Therapeutic agent and method for treating non-alcoholic fatty liver disease (U.S. Patent No. 9,937,132). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
